Latest stories on DMAC
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger
Seeking Alpha63 · neutralproduct/pr
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration
TipRanks50 · neutralgeneral
DiaMedica Therapeutics GAAP EPS of -$0.19 beats by $0.01
Seeking Alpha56 · neutralearnings
DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)
The Fly47 · neutralearnings
DiaMedica Therapeutics Inc. (DMAC) files 8-K
SEC 8-K50 · neutralgeneral
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
StockTitan59 · neutralearnings
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
StockTitan50 · neutralgeneral
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
Yahoo Finance63 · neutralproduct/pr
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program | DMAC Stock News
StockTitan56 · neutralproduct/pr
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 | DMAC Stock News
StockTitan56 · neutralgeneral